Location:Room 16, Capital suite (level 3)
Early results from immunotherapy trials in the salvage setting of advanced/metastatic urothelial bladder cancer (UBC) paved the way of a revolutionary road in the treatment of this disease.
Atezolizumab, an anti-programmed cell death ligand-1 (PD-L1) antibody, was recently granted conditional approval by the U.S. Food and Drug Administration (FDA) for the treatment of advanced or metastatic UBC after platinum chemotherapy (IMvigor 210 study).
Pembrolizumab, an anti-PD-1 antibody, has just demontrated, for the first time in this disease, overall survival advantage compared to active therapy in a phase 3, multicenter, randomized trial (Keynote-045 study) of salvage therapy.
Other immune checkpoint inhibitors have been positively investigated, and a myriad of clinical trials are being developed in UBC worldwide in different clinical settings, including the non-muscle invasive disease.
Consequently, urologists are asked to understand the background of immunotherapy in UBC, the achievable results and side effects, and to know which are the ongoing and future therapeutic options for their patients, provided either inside or outside of clinical trials.
In brief, the aims will be the following:
• To provide urologists with the state-of-the art with the use of immune-checkpoint inhibitors in UBC.
• To provide urologists with the next clinical trials in the setting of non-muscle invasive and muscle invasive metastatic disease, and in the perioperative setting (before or after surgery).
• To provide an overview of the immunological background of the mode of action of checkpoint inhibitors in bladder carcinoma
• To discuss the optimal clinical management of patients receiving immune checkpoint inhibitor treatment, including side effects.